Chemical: Drug
dexamethasone

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


1. FDA Label for dexamethasone

Full label available at DailyMed

Genes and/or phenotypes found in this label


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for dexamethasone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA UGT1A1 *6 N/A N/A N/A
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs1138518 NC_000003.11:g.46944274T>C, NC_000003.12:g.46902784T>C, NG_008864.1:g.30039T>C, NM_000316.2:c.1389T>C, NM_001184744.1:c.1389T>C, NP_000307.1:p.Asn463=, NP_001171673.1:p.Asn463=, XM_005265341.1:c.1428T>C, XM_005265342.1:c.1389T>C, XM_005265343.1:c.1335T>C, XM_005265344.1:c.1296T>C, XM_005265344.2:c.1296T>C, XM_011533967.1:c.1428T>C, XM_011533968.1:c.1410T>C, XP_005265398.1:p.Asn476=, XP_005265399.1:p.Asn463=, XP_005265400.1:p.Asn445=, XP_005265401.1:p.Asn432=, XP_011532269.1:p.Asn476=, XP_011532270.1:p.Asn470=, rs11545034, rs17435012, rs1869872, rs3202529, rs58779339
T > C
SNP
N463N
VIP No Clinical Annotations available No Variant Annotations available
rs11568820 NC_000012.11:g.48302545C>T, NC_000012.12:g.47908762C>T, NG_008731.1:g.1270G>A, rs17883968, rs56977367, rs60432410
C > T
SNP
No VIP available CA VA
rs117532069 NC_000020.10:g.53301068G>A, NC_000020.11:g.54684529G>A
G > A
SNP
No VIP available CA VA
rs141059755 NC_000008.10:g.66107605A>C, NC_000008.10:g.66107605A>G, NC_000008.11:g.65195370A>C, NC_000008.11:g.65195370A>G
A > C
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1695 NC_000011.10:g.67585218A>G, NC_000011.9:g.67352689A>G, NG_012075.1:g.6624A>G, NM_000852.3:c.313A>G, NP_000843.1:p.Ile105Val, XM_005273958.1:c.313A>G, XP_005274015.1:p.Ile105Val, rs1138257, rs11553891, rs17353321, rs17856342, rs2230827, rs4609, rs56971933, rs947894
A > G
SNP
I105V
No VIP available CA VA
rs17021408 NC_000001.10:g.213943238T>C, NC_000001.11:g.213769895T>C, XR_922586.1:n.137-24489T>C, XR_922587.1:n.136+38337T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1800247 NC_000001.10:g.156211825T>C, NC_000001.11:g.156242034T>C, NM_001199661.1:c.504-519T>C, NM_001199662.1:c.565-519T>C, NM_001199663.1:c.369-519T>C, NM_001199664.1:c.358-519T>C, NM_199173.5:c.-198T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available CA VA
rs1891059 NC_000001.10:g.213946009G>A, NC_000001.11:g.213772666G>A, XR_922586.1:n.137-21718G>A, XR_922587.1:n.136+41108G>A
G > A
SNP
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs2228570 NC_000012.11:g.48272895A>G, NC_000012.12:g.47879112A>G, NG_008731.1:g.30920T>C, NM_000376.2:c.2T>C, NM_001017535.1:c.2T>C, NM_001017536.1:c.152T>C, NP_000367.1:p.Met1Thr, NP_001017535.1:p.Met1Thr, NP_001017536.1:p.Met51Thr, XM_006719587.2:c.2T>C, XM_011538720.1:c.2T>C, XP_006719650.1:p.Met1Thr, XP_011537022.1:p.Met1Thr, rs10735810, rs117559231, rs17881966, rs52811041, rs56641119, rs57067622, rs8179174
A > G
SNP
M1T
No VIP available No Clinical Annotations available VA
rs2229531 NC_000019.10:g.11576380C>T, NC_000019.9:g.11687195C>T, NG_028127.1:g.7607G>A, NM_001111034.1:c.598G>A, NM_001111035.1:c.598G>A, NM_001111036.1:c.598G>A, NM_001611.3:c.598G>A, NP_001104504.1:p.Val200Met, NP_001104505.1:p.Val200Met, NP_001104506.1:p.Val200Met, NP_001602.1:p.Val200Met, XM_005259938.1:c.598G>A, XM_005259939.1:c.598G>A, XM_005259939.3:c.598G>A, XM_011527780.1:c.-94+1027C>T, XM_011528069.1:c.598G>A, XP_005259995.1:p.Val200Met, XP_005259996.1:p.Val200Met, XP_011526371.1:p.Val200Met, rs59380162
C > T
SNP
V200M
No VIP available No Clinical Annotations available VA
rs2234693 NC_000006.11:g.152163335T>C, NC_000006.12:g.151842200T>C, NG_008493.1:g.156705T>C, NM_000125.3:c.453-397T>C, NM_001122740.1:c.453-397T>C, NM_001122741.1:c.453-397T>C, NM_001122742.1:c.453-397T>C, NM_001291230.1:c.453-397T>C, NM_001291241.1:c.453-397T>C, XM_005266856.1:c.453-397T>C, XM_005266857.1:c.453-397T>C, XM_006715374.2:c.453-397T>C, XM_006715375.2:c.-67-397T>C, XM_011535543.1:c.453-397T>C, XM_011535544.1:c.453-397T>C, XM_011535545.1:c.453-397T>C, XM_011535546.1:c.453-397T>C, XM_011535547.1:c.453-397T>C, XM_011535548.1:c.-67-397T>C, rs4134641, rs60769286
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2275622 NC_000010.10:g.96827178T>C, NC_000010.11:g.95067421T>C, NG_007972.1:g.7077A>G, NM_000770.3:c.332-64A>G, NM_001198853.1:c.122-64A>G, NM_001198854.1:c.26-64A>G, NM_001198855.1:c.122-64A>G, XR_246073.1:n.428-64A>G, XR_945610.1:n.428-64A>G, rs17110450, rs57064143
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2305799 NC_000019.10:g.11576536C>T, NC_000019.9:g.11687351C>T, NG_028127.1:g.7451G>A, NM_001111034.1:c.442G>A, NM_001111035.1:c.442G>A, NM_001111036.1:c.442G>A, NM_001611.3:c.442G>A, NP_001104504.1:p.Val148Met, NP_001104505.1:p.Val148Met, NP_001104506.1:p.Val148Met, NP_001602.1:p.Val148Met, XM_005259938.1:c.442G>A, XM_005259939.1:c.442G>A, XM_005259939.3:c.442G>A, XM_011527780.1:c.-94+1183C>T, XM_011528069.1:c.442G>A, XP_005259995.1:p.Val148Met, XP_005259996.1:p.Val148Met, XP_011526371.1:p.Val148Met, rs52817235
C > T
SNP
V148M
No VIP available No Clinical Annotations available VA
rs2306862 NC_000011.10:g.68410042C>T, NC_000011.9:g.68177510C>T, NG_015835.1:g.102403C>T, NM_001291902.1:c.477C>T, NM_002335.3:c.2220C>T, NP_001278831.1:p.Asn159=, NP_002326.2:p.Asn740=, XM_005273994.1:c.2220C>T, XM_005273994.2:c.2220C>T, XM_011545029.1:c.2247C>T, XM_011545030.1:c.2247C>T, XM_011545031.1:c.2247C>T, XP_005274051.1:p.Asn740=, XP_011543331.1:p.Asn749=, XP_011543332.1:p.Asn749=, XP_011543333.1:p.Asn749=, XR_949925.1:n.2262C>T, XR_949926.1:n.2262C>T, rs17847936, rs59591801
C > T
SNP
N159N
No VIP available CA VA
rs3824662 NC_000010.10:g.8104208C>A, NC_000010.11:g.8062245C>A, NG_015859.1:g.12542C>A, NM_001002295.1:c.779-1748C>A, NM_002051.2:c.779-1751C>A, XM_005252442.1:c.779-1748C>A, XM_005252442.2:c.779-1748C>A, XM_005252443.1:c.779-1748C>A, XM_005252443.3:c.779-1748C>A, rs11567915
C > A
SNP
No VIP available CA VA
rs4135385 NC_000003.11:g.41279440A>G, NC_000003.12:g.41237949A>G, NG_013302.1:g.43499A>G, NM_001098209.1:c.2077-67A>G, NM_001098210.1:c.2077-67A>G, NM_001904.3:c.2077-67A>G, XM_005264886.1:c.2077-67A>G, XM_005264886.2:c.2077-67A>G, XM_005264887.1:c.2077-67A>G, XM_005264888.1:c.2077-67A>G, XM_006712983.1:c.2056-67A>G, XM_006712984.1:c.2056-67A>G, XM_006712985.1:c.2076+1240A>G, rs58718635
A > G
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs4516035 NC_000012.11:g.48299826T>C, NC_000012.12:g.47906043T>C, NG_008731.1:g.3989A>G, NM_000376.2:c.-1172A>G, NM_001017535.1:c.-1294A>G, NM_001017536.1:c.-1413A>G, XM_006719587.2:c.-1091A>G, XM_011538720.1:c.-1213A>G, rs17396597, rs17882742, rs58063668
T > C
SNP
No VIP available No Clinical Annotations available VA
rs45445694 NC_000018.10:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.9:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NG_028255.1:g.5043_5070CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NM_001012716.2:c.*34+169_*34+196CGGGACGGAGGCAGGCCAAGTGGCGCGG[2][3][4][7][8][9], NM_001071.2:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], XM_005258137.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], XM_005258138.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9]
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)4
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)7
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)8
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)9
microsatellite
No VIP available CA VA
rs4553808 NC_000002.11:g.204731005A>G, NC_000002.12:g.203866282A>G, NG_011502.1:g.3497A>G, NM_001037631.2:c.-1661A>G, NM_005214.4:c.-1661A>G, XR_241294.1:n.-1521A>G, rs61636940
A > G
SNP
No VIP available No Clinical Annotations available VA
rs4630 NC_000022.10:g.24376322G>A, NM_000853.3:c.*101C>T, NM_001293807.1:c.*101C>T, NM_001293808.1:c.*101C>T, NM_001293809.1:c.*101C>T, NM_001293810.1:c.*101C>T, NM_001293811.1:c.*101C>T, NM_001293812.1:c.*101C>T, NM_001293813.1:c.*178C>T, NM_001293814.1:c.*189C>T, NR_132348.1:n.360G>A, NT_187633.1:g.270497G>A, XM_005261587.1:c.*101C>T, XM_005261587.2:c.*101C>T, XM_005261588.1:c.*101C>T, XM_005261589.1:c.*101C>T, rs1065851, rs2250160, rs3190565, rs772061188
G > A
SNP
No VIP available CA VA
rs6092 NC_000007.13:g.100771717G>A, NC_000007.14:g.101128436G>A, NG_013213.1:g.6339G>A, NM_000602.4:c.43G>A, NP_000593.1:p.Ala15Thr, XM_005250392.1:c.43G>A, XP_005250449.1:p.Ala15Thr, rs11553531, rs52825313
G > A
SNP
A15T
No VIP available No Clinical Annotations available VA
rs6254 NC_000011.10:g.13492716C>T, NC_000011.9:g.13514263C>T, NG_008962.1:g.8305G>A, NM_000315.3:c.87-50G>A, NM_001316352.1:c.183-50G>A, rs17526181, rs56632183, rs61242134
C > A
C > T
SNP
No VIP available CA VA
rs7142143 NC_000014.8:g.51403531T>C, NC_000014.9:g.50936813T>C, NG_012796.1:g.12718A>G, NM_001163940.1:c.244-1628A>G, NM_002863.3:c.345+923A>G, NM_002863.4:c.345+923A>G, rs111177964, rs57811686
T > C
SNP
No VIP available No Clinical Annotations available VA
rs735482 NC_000019.10:g.45408744A>C, NC_000019.9:g.45912002A>C, NG_015839.2:g.75085T>G, NM_001166049.1:c.*931T>G, NM_001297590.1:c.782A>C, NM_001983.3:c.*931T>G, NM_012099.1:c.776A>C, NP_001284519.1:p.Lys261Thr, NP_036231.1:p.Lys259Thr, XM_005258425.1:c.782A>C, XM_005258638.1:c.*931T>G, XP_005258482.1:p.Lys261Thr, rs61340218
A > C
A > G
SNP
K261T
No VIP available CA VA
rs79085477 NC_000020.10:g.55701215C>T, NC_000020.11:g.57126159C>T, XR_936901.1:n.278+5836G>A, XR_936902.1:n.89+350G>A, XR_936903.1:n.48+399G>A, XR_936904.1:n.278+5836G>A
C > T
SNP
No VIP available CA VA
rs80223967 NC_000001.10:g.213943679A>G, NC_000001.11:g.213770336A>G, XR_922586.1:n.137-24048A>G, XR_922587.1:n.136+38778A>G
A > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • DEX
  • DXM
  • Desametasone
  • Desametasone [Dcit]
  • Desamethasone
  • Dexametasona [INN-Spanish]
  • Dexamethasone Acetate
  • Dexamethasone Alcohol
  • Dexamethasone Base
  • Dexamethasone Sodium Phosphate
  • Dexamethasonum [INN-Latin]
  • Dexamethazone
  • Dxms
  • Fluormethylprednisolone
  • dexamethasone
Trade Names
  • Adexone
  • Aeroseb-D
  • Aeroseb-Dex
  • Anaflogistico
  • Aphtasolon
  • Aphthasolone
  • Auxiron
  • Azium
  • Bisu Ds
  • Calonat
  • Corson
  • Corsone
  • Cortisumman
  • Decacort
  • Decacortin
  • Decaderm
  • Decadron
  • Decadron Tablets, Elixir
  • Decadron-La
  • Decagel
  • Decalix
  • Decasone
  • Decaspray
  • Dectancyl
  • Dekacort
  • Deltafluorene
  • Dergramin
  • Deronil
  • Desadrene
  • Desameton
  • Deseronil
  • Dex-Ide
  • Dexa
  • Dexa Mamallet
  • Dexa-Cortidelt
  • Dexa-Cortisyl
  • Dexa-Mamallet
  • Dexa-Scheroson
  • Dexa-Sine
  • Dexacen-4
  • Dexacidin
  • Dexacort
  • Dexacortal
  • Dexacortin
  • Dexadeltone
  • Dexafarma
  • Dexair
  • Dexalona
  • Dexaltin
  • Dexameth
  • Dexamethasone Intensol
  • Dexamonozon
  • Dexapolcort
  • Dexapos
  • Dexaprol
  • Dexason
  • Dexasone
  • Dexinolon
  • Dexinoral
  • Dexone
  • Dexone 0.5
  • Dexone 0.75
  • Dexone 1.5
  • Dexone 4
  • Dexonium
  • Dextelan
  • Dezone
  • Dinormon
  • Fluormone
  • Fluorocort
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Hexadrol Elixir
  • Hexadrol Tablets
  • Hl-Dex
  • IontoDex
  • Isopto-Dex
  • Lokalison F
  • Loverine
  • Luxazone
  • Maxidex
  • Maxitrol
  • Mediamethasone
  • Mexidex
  • Millicorten
  • Mymethasone
  • Ocu-Trol
  • Oradexon
  • Pet Derm Iii
  • Pet-Derm Iii
  • Policort
  • Posurdex
  • Prednisolon F
  • Prednisolone F
  • Sk-Dexamethasone
  • Spoloven
  • Sunia Sol D
  • Superprednol
  • Turbinaire
  • Visumetazone
Brand Mixture Names
  • Ak Trol Suspension (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate)
  • Ciprodex (Ciprofloxacin (Ciprofloxacin Hydrochloride) + Dexamethasone)
  • Cresophene Liq (Camphor + Chlorophenol + Dexamethasone + Thymol)
  • Dioptrol Ointment (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate)
  • Dioptrol Suspension (Dexamethasone + Neomycin (Neomycin Sulfate) + Polymyxin B Sulfate)
  • Endomethasone Ivory (Dexamethasone + Hydrocortisone Acetate + Paraformaldehyde + Thymol Iodide)
  • Maxitrol (Dexamethasone + Neomycin (Neomycin Sulfate) + Polymyxin B Sulfate)
  • Maxitrol Ont (Dexamethasone + Neomycin (Neomycin Sulfate) + Polymyxin B Sulfate)
  • Naquasone Bolus (Dexamethasone + Trichlormethiazide)
  • Naquasone Inj (Dexamethasone + Trichlormethiazide)
  • Neodecadron Eye Ear Soln 0.1% (Dexamethasone Phosphate (Dexamethasone Sodium Phosphate) + Neomycin Sulfate)
  • Pendamine (Chlorpheniramine Maleate + Dexamethasone + Dihydrostreptomycin Sulfate + Penicillin G Procaine)
  • Sandoz Opticort (Dexamethasone (Dexamethasone Sodium Metasulphobenzoate) + Framycetin Sulfate + Gramicidin)
  • Septomixine Forte (Dexamethasone + Halethazole Tartrate + Neomycin (Neomycin Sulfate) + Polymyxin B Sulfate + Tyrothricin)
  • Sofracort Ear/Eye Ointment (Dexamethasone + Framycetin Sulfate + Gramicidin)
  • Sofracort Eye/Ear Drops (Dexamethasone Sodium Metasulphobenzoate + Framycetin Sulfate + Gramicidin)
  • Sofracort Sterile Ear/Eye Drops (Dexamethasone (Dexamethasone Sodium Metasulphobenzoate) + Framycetin Sulfate + Gramicidin)
  • Sofracort Sterile Ear/Eye Ointment (Dexamethasone + Framycetin Sulfate + Gramicidin)
  • Tobradex Oph Ointment (Dexamethasone + Tobramycin)
  • Tobradex Oph Sus (Dexamethasone + Tobramycin)
  • Tresaderm Dermatologic Solution (Dexamethasone + Neomycin (Neomycin Sulfate) + Thiabendazole)

PharmGKB Accession Id

PA449247

Type(s):

Drug

Description

An anti-inflammatory 9-fluoro-glucocorticoid.

Source: Drug Bank

Indication

Injection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
<br>*Ophthalmic ointment and solution:* for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
<br>*Ophthalmic solution only:* for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
<br>*Topic cream:* for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
<br>*Oral aerosol:* for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
<br>*Intranasal aerosol:* for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A 2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Source: Drug Bank

Pharmacology

Dexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take with food to reduce irritation.|Avoid taking with grapefruit juice.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic.

Source: Drug Bank

Protein Binding

70%

Source: Drug Bank

Absorption

80-90%

Source: Drug Bank

Half-Life

36-54 hours

Source: Drug Bank

Toxicity

Oral, rat LD 50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H29FO5

Source: Drug Bank

Isomeric SMILES

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C

Source: OpenEye

Canonical SMILES

C[C@@H]1C[C@H]

Source: Drug Bank

Average Molecular Weight

392.4611

Source: Drug Bank

Monoisotopic Molecular Weight

392.199902243

Source: Drug Bank

SMILES

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Source: Drug Bank

InChI String

InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Etoposide Pathway, Pharmacokinetics/Pharmacodynamics
    Etoposide cellular disposition and effects.
  1. Glucocorticoid Pathway (Peripheral Tissue), Pharmacodynamics
    Genes involved in mediating glucocorticoid effects at the tissue level in the CNS and in the peripheral tissues including heart, lung, vasculatrue and guts.
  1. Glucocorticoid Pathway - Transcription Regulation, Pharmacodynamics
    Model displaying genes which may be involved in the nuclear complex formed that regulates transcription in response to glucocorticoids.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ANXA1 (source: Drug Bank)
CXCL12 (source: Drug Bank)
NFKB1 (source: Drug Bank)
NOS2 (source: Drug Bank)
NR0B1 (source: Drug Bank)
NR3C1 (source: Drug Bank)

Drug Interactions

Interaction Description
aminoglutethimide - dexamethasone Decreases the effect of dexamethasone (source: Drug Bank)
aminoglutethimide - dexamethasone Aminoglutethimide may decrease the effect of dexamethasone. (source: Drug Bank)
aprepitant - dexamethasone Increases the effect and toxicity of dexamethasone (source: Drug Bank)
aspirin - dexamethasone The corticosteroid decreases the effect of salicylates (source: Drug Bank)
aspirin - dexamethasone The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
dexamethasone - acenocoumarol The corticosteroid alters the anticoagulant effect (source: Drug Bank)
dexamethasone - acenocoumarol The corticosteroid, dexamethasone, alters the anticoagulant effect, acenocoumarol. (source: Drug Bank)
dexamethasone - ambenonium The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, ambenonium. (source: Drug Bank)
dexamethasone - aminoglutethimide Aminogluthetimide decreases the effect of dexamethasone (source: Drug Bank)
dexamethasone - aminoglutethimide Aminogluthetimide decreases the effect of dexamethasone (source: Drug Bank)
dexamethasone - amobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - amobarbital The barbiturate, amobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - anisindione The corticosteroid, dexamethasone, alters the anticoagulant effect of anisindione. (source: Drug Bank)
dexamethasone - aprepitant Aprepitant increases the effect and toxicity of dexamethasone (source: Drug Bank)
dexamethasone - aprobarbital The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - aspirin The corticosteroid decreases the effect of salicylates (source: Drug Bank)
dexamethasone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - butalbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - butalbital The barbiturate, butalbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - butethal The barbiturate, butethal, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - dicumarol The corticosteroid alters the anticoagulant effect (source: Drug Bank)
dexamethasone - dicumarol The corticosteroid, dexamethasone, alters the anticoagulant effect of dicumarol. (source: Drug Bank)
dexamethasone - edrophonium The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank)
dexamethasone - edrophonium The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, edrophonium. (source: Drug Bank)
dexamethasone - ethotoin The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - fosphenytoin The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - heptabarbital The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - hexobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - hexobarbital The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - imatinib Decreases levels of imatinib (source: Drug Bank)
dexamethasone - imatinib Decreases levels of imatinib (source: Drug Bank)
dexamethasone - mephenytoin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - mephenytoin The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - methohexital The barbiturate, methohexital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - methylphenobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - methylphenobarbital The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - midodrine Increased arterial pressure (source: Drug Bank)
dexamethasone - neostigmine The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank)
dexamethasone - neostigmine The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, neostigmine. (source: Drug Bank)
dexamethasone - pentobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - pentobarbital The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - phenobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - phenobarbital The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - phenytoin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - phenytoin The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - primidone The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - primidone The barbiturate, primidone, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - pyridostigmine The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank)
dexamethasone - pyridostigmine The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine. (source: Drug Bank)
dexamethasone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - rifampin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone - rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - salicylate-magnesium The corticosteroid decreases the effect of salicylates (source: Drug Bank)
dexamethasone - salsalate The corticosteroid, dexamethasone, may decrease the effect of the salicylate, salsalate. (source: Drug Bank)
dexamethasone - secobarbital The barbiturate, secobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - sunitinib Possible decrease in sunitinib levels (source: Drug Bank)
dexamethasone - sunitinib Possible decrease in sunitinib levels (source: Drug Bank)
dexamethasone - talbutal The barbiturate, talbutal, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
dexamethasone - warfarin The corticosteroid alters the anticoagulant effect (source: Drug Bank)
dexamethasone - warfarin The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin. (source: Drug Bank)
fosphenytoin - dexamethasone The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
imatinib - dexamethasone Dexamethasone decreases levels of imatinib (source: Drug Bank)
imatinib - dexamethasone Dexamethasone decreases levels of imatinib (source: Drug Bank)
midodrine - dexamethasone Increased arterial pressure (source: Drug Bank)
phenobarbital - dexamethasone The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
phenobarbital - dexamethasone The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
phenytoin - dexamethasone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
phenytoin - dexamethasone The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
primidone - dexamethasone The barbiturate decreases the effect of the corticosteroid (source: Drug Bank)
primidone - dexamethasone The barbiturate, primidone, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
pyridostigmine - dexamethasone The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank)
pyridostigmine - dexamethasone The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine. (source: Drug Bank)
rifampin - dexamethasone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
rifampin - dexamethasone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
tacrine - dexamethasone Tacrine and Dexamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects. (source: Drug Bank)
telithromycin - dexamethasone Co-administration may cause decreased Telithromycin and increased Dexamethasone plasma concentrations. Consider alternate therapy. (source: Drug Bank)
thalidomide - dexamethasone Increased risk of dermatologic adverse effects and venous thromboembolic events (VTE). Consider VTE prophylaxis during concomitant therapy and monitor for adverse dematologic effects. (source: Drug Bank)
tramadol - dexamethasone Dexamethasone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. (source: Drug Bank)
trastuzumab - dexamethasone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. (source: Drug Bank)
trazodone - dexamethasone The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed. (source: Drug Bank)
trazodone - dexamethasone The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed. (source: Drug Bank)
voriconazole - dexamethasone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dexamethasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dexamethasone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Diagnoses
Contraindicated With

Publications related to dexamethasone: 59

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model. PloS one. 2016. Liu Chengcheng, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood. 2015. Karol Seth E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leukemia research. 2015. Butrym Aleksandra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Pui Ching-Hon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan. Annals of hematology. 2014. Yamasaki Satoshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RNA-Seq Transcriptome Profiling Identifies CRISPLD2 as a Glucocorticoid Responsive Gene that Modulates Cytokine Function in Airway Smooth Muscle Cells. PloS one. 2014. Himes Blanca E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature genetics. 2013. Perez-Andreu Virginia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. The American journal of pathology. 2013. Janke Laura J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013. Vrooman Lynda M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013. Relling Mary V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood. 2012. Yang Jun J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary for VDR. Pharmacogenetics and genomics. 2012. Poon Audrey H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2011. Kawedia Jitesh D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature genetics. 2011. Yang Jun J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenetics and genomics. 2011. Favis Reyna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2010. Kawedia Jitesh D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological reports : PR. 2011. Baer-Dubowska Wanda, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Quantitative analysis and modeling of glucocorticoid-controlled gene expression. Pharmacogenomics. 2010. Chen Daphne Wei-Chen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics. 2010. Morag Ayelet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2010. Pui C H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 2010. Ramakrishnan V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. The Laryngoscope. 2009. Grau Juan J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacoepigenetics: its role in interindividual differences in drug response. Clinical pharmacology and therapeutics. 2009. Gomez A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008. French Deborah, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenetics and genomics. 2008. Maggini Valentina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Molecular pharmacology. 2008. Onica Tania, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. The New England journal of medicine. 2007. Scarborough Matthew, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. The New England journal of medicine. 2007. Nguyen Thi Hoang Mai, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New England journal of medicine. 2007. Weber Donna M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England journal of medicine. 2007. Dimopoulos Meletios, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007. Kishi Shinji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Current opinion in ophthalmology. 2006. Jones Relief, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005. Rocha Jose Claudio C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition by dexamethasone of interleukin 13 production via glucocorticoid receptor-mediated inhibition of c-Jun phosphorylation. FEBS letters. 2003. Hirasawa Noriyasu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tissue-specific regulation of the human acute-phase serum amyloid A genes, SAA1 and SAA2, by glucocorticoids in hepatic and epithelial cells. European journal of immunology. 2003. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. European journal of pharmacology. 2003. Krusekopf Solveigh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual review of pharmacology and toxicology. 2003. Ding Xinxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology. 2002. Webster Jeffrey C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2002. Luo Gang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. Journal of immunology (Baltimore, Md. : 1950). 2002. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
LPS-induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is increased but supersensitive to inhibition by dexamethasone. Journal of neuroimmunology. 2001. Visser J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Molecular and cellular biology. 2001. Lasa M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clinical pharmacology and therapeutics. 2000. McCune J S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 2000. Xie W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica; the fate of foreign compounds in biological systems. 2000. Meunier V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittel-Forschung. 1998. Smith C L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. The Journal of clinical investigation. 1998. Lehmann J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Modulation of Mycoplasma arthritidis-derived superantigen-induced cytokine gene expression by dexamethasone and interleukin-4. Infection and immunity. 1994. Mehindate K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Molecular pharmacology. 1994. Relling M V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1994. Kletzien R F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of interleukin-5 gene expression by dexamethasone. Immunology. 1992. Rolfe F G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
T cell receptor-independent immunosuppression induced by dexamethasone in murine T helper cells. The Journal of clinical investigation. 1992. Sierra-Honigmann M R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Molecular and cellular biology. 1990. Ray A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rapid development of enhanced clearance after high-dose cyclophosphamide. Clinical pharmacology and therapeutics. 1988. Moore M J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. Journal of immunology (Baltimore, Md. : 1950). 1987. Knudsen P J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Regulation of IL 3 expression by glucocorticoids in cloned murine T lymphocytes. Journal of immunology (Baltimore, Md. : 1950). 1985. Culpepper J A, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0703-3524-03
DrugBank:
DB01234
PDB:
DEX
ChEBI:
41879
KEGG Drug:
D00292
PubChem Compound:
5743
PubChem Substance:
46508930
Drugs Product Database (DPD):
664227
BindingDB:
18207
ChemSpider:
5541
HET:
DEX
Therapeutic Targets Database:
DAP000007

Clinical Trials

These are trials that mention dexamethasone and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.